Home Blog Page 4

Gene Fusion Panel Test: Cancer Fusions, Rearrangement Markers, and Molecular Tumor Classification

Learn how a gene fusion panel detects cancer rearrangements, why RNA-based NGS is useful, what positive and negative results mean, and how fusions can guide tumor classification and targeted therapy.

A gene fusion panel tests a tumor for abnormal gene pairings created when chromosomes rearrange. These fusions can act as cancer drivers, help identify...

HER2/ERBB2 Mutation Test: Breast, Gastric, Lung Cancer, Mutation Status, and HER2 Meaning

Learn what a HER2/ERBB2 mutation test means in lung, breast, and gastric cancer, how mutations differ from HER2 amplification or IHC, and how results can guide targeted treatment.

A HER2/ERBB2 mutation test looks for DNA changes in the ERBB2 gene, which encodes the HER2 receptor. The result is not the same as...

Homologous Recombination Deficiency (HRD) Test: DNA Repair Deficiency, Ovarian Cancer, and Genomic Score

Learn what an HRD test measures in ovarian cancer, how genomic instability scores and BRCA status are interpreted, what HRD-positive means, and how results can inform PARP inhibitor treatment decisions.

A homologous recombination deficiency, or HRD, test looks for evidence that a tumor has lost an important high-accuracy DNA repair pathway. In ovarian cancer,...

HRAS Mutation Test: Head and Neck Cancer, Thyroid Cancer, Mutation Status, and Meaning

Learn what an HRAS mutation test means in head and neck cancer and thyroid disease, how hotspot and VAF results are interpreted, and why a positive HRAS result has different implications by tumor type.

An HRAS mutation test looks for activating DNA changes in the HRAS gene, one of the RAS family genes that control cell growth signaling....

IDH1 Mutation Test: Glioma, Leukemia, Cholangiocarcinoma, Mutation Status, and Meaning

Learn what an IDH1 mutation test means in glioma, AML, and cholangiocarcinoma, how R132 mutations are detected, and how positive results can affect diagnosis and targeted treatment.

An IDH1 mutation test looks for abnormal changes in the IDH1 gene, most commonly at amino acid R132. These mutations alter cell metabolism and...

IDH2 Mutation Test: Leukemia, Glioma, Cholangiocarcinoma, Mutation Status, and Meaning

Understand what an IDH2 mutation test means in AML, glioma, and cholangiocarcinoma, including positive and negative results, treatment relevance, testing methods, and important limitations.

An IDH2 mutation test looks for specific changes in the IDH2 gene that can help classify a tumor, explain part of its biology, and...

KIT Mutation Test: GIST, Melanoma, Mast Cell Disease, Mutation Status, and Meaning

Learn what a KIT mutation test means in GIST, melanoma, and mast cell disease, including exon-specific results, KIT D816V, treatment relevance, CD117 differences, and testing limitations.

A KIT mutation test looks for DNA changes that activate the KIT receptor tyrosine kinase. The result can be highly important, but its meaning...

KRAS Mutation Test: Colon, Lung, Pancreatic Cancer, Mutation Status, and Result Meaning

Understand KRAS mutation test results in colon, lung, and pancreatic cancer, including G12C, G12D, treatment resistance, targeted therapy, negative results, and testing limits.

A KRAS mutation test looks for activating changes in the KRAS gene that can influence cancer classification and treatment. KRAS is one of the...

MDM2 Amplification Test: Liposarcoma, Copy Number Gain, Tumor Diagnosis, and FISH Result

Understand MDM2 amplification testing for liposarcoma, including FISH ratios, copy number gain, polysomy, positive and negative results, diagnostic pitfalls, and next steps.

An MDM2 amplification test checks whether tumor cells contain many extra copies of the MDM2 gene. The test is especially useful when a pathologist...

MET Amplification Test: Lung Cancer, Gastric Cancer, Copy Number Gain, and Result Meaning

Understand MET amplification test results in lung and gastric cancer, including FISH ratios, NGS copy number, polysomy, high-level amplification, resistance, and treatment implications.

A MET amplification test checks whether tumor cells contain extra copies of the MET gene, which can activate growth signaling and sometimes create a...

Microsatellite Instability (MSI) Test: Lynch Syndrome, Mismatch Repair, Cancer Risk, and Result Meaning

Understand MSI test results for Lynch syndrome and cancer care, including MSI-H, MSS, mismatch repair deficiency, immunotherapy relevance, hereditary follow-up, discordant results, and next steps.

A microsatellite instability (MSI) test evaluates whether a tumor has accumulated abnormal length changes in short repetitive DNA sequences because the DNA mismatch repair...

Mismatch Repair (MMR) Gene Test: MLH1, MSH2, MSH6, PMS2, and Lynch Syndrome

Understand MMR gene testing for MLH1, MSH2, MSH6, PMS2, EPCAM, and Lynch syndrome, including IHC patterns, MSI, germline results, cancer risk, and next steps.

A mismatch repair (MMR) gene test evaluates genes that protect DNA from copying errors, most importantly MLH1, MSH2, MSH6, and PMS2, with EPCAM also...

MLH1 Mutation Test: Lynch Syndrome, Colon Cancer, Mismatch Repair, and Variant Meaning

Understand MLH1 mutation testing for Lynch syndrome and colon cancer, including MLH1/PMS2 loss, promoter methylation, BRAF triage, germline variants, cancer risk, and result meaning.

An MLH1 mutation test can be used to look for an inherited pathogenic variant that causes Lynch syndrome or to characterize changes found in...

MPL Mutation Test: Myeloproliferative Neoplasm, Platelets, Thrombocytosis, and Result Meaning

Understand MPL mutation test results in thrombocytosis and myeloproliferative neoplasms, including W515 variants, ET versus myelofibrosis, negative results, VAF, prognosis, and next steps.

An MPL mutation test looks for activating changes in the MPL gene, which encodes the thrombopoietin receptor that helps control platelet production and blood-cell...

MSH2 Mutation Test: Lynch Syndrome, Colon Cancer, Mismatch Repair, and Variant Meaning

Understand MSH2 mutation testing for Lynch syndrome, including MSH2/MSH6 loss, EPCAM deletions, germline results, colorectal and urinary-tract cancer risk, MSI, and next steps.

An MSH2 mutation test can identify an inherited pathogenic variant that causes Lynch syndrome or clarify an abnormal mismatch repair result found in a...

MSH6 Mutation Test: Lynch Syndrome, Colon Cancer, Mismatch Repair, and Variant Meaning

Understand MSH6 mutation testing for Lynch syndrome, including isolated MSH6 loss, MSI findings, germline variants, colorectal and endometrial cancer risk, surveillance, and next steps.

An MSH6 mutation test can identify an inherited pathogenic variant that causes Lynch syndrome or help explain abnormal mismatch repair findings in a tumor....

MUTYH Mutation Test: Colon Cancer, Polyposis, Variant Meaning, and Hereditary Risk

Understand MUTYH mutation testing, including biallelic versus monoallelic results, polyposis and colon cancer risk, variant meaning, surveillance, and family testing.

A MUTYH mutation test looks for inherited changes in the MUTYH gene that can raise the risk of colorectal polyps and colorectal cancer. The...

MYC Rearrangement Test: Lymphoma, Leukemia, High-Grade Disease, and FISH Result

Learn what a MYC rearrangement FISH test detects, how positive and negative results are interpreted, and what MYC means in Burkitt, high-grade B-cell lymphoma, and leukemia.

A MYC rearrangement test looks for a structural change involving the MYC gene, usually with fluorescence in situ hybridization (FISH). MYC is a powerful...

MYD88 Mutation Test: Waldenstrom Macroglobulinemia, Lymphoma, L265P Variant, and Meaning

Understand MYD88 L265P testing in Waldenström macroglobulinemia and lymphoma, including positive and negative results, test methods, CXCR4 context, and treatment meaning.

A MYD88 mutation test looks for acquired changes in the MYD88 gene in abnormal B cells. The best-known result is MYD88 L265P, a hotspot...

NPM1 Mutation Test: AML Prognosis, MRD Monitoring, Mutation Status, and Meaning

Understand NPM1 mutation testing in AML, including prognosis, FLT3 risk groups, molecular MRD monitoring, positive and negative results, and what changing NPM1 levels mean.

An NPM1 mutation test looks for acquired changes in the nucleophosmin 1 gene that define one of the largest molecular subgroups of acute myeloid...